Investor Presentaiton slide image

Investor Presentaiton

For personal use only TLX250-CDx / TLX250 overview An exciting target, with potential application beyond kidney cancer Target: Carbonic Anhydrase IX (CAIX / CA9) . Indication: Kidney cancer (clear cell renal cell carcinoma, ccRCC) Target: CAIX / CA9 Dx (TLX 250-CDX) Tx (TLX250) Development status: • TLX 250-CDx: Phase III ZIRCON diagnostic imaging study nearing completion Targeting molecule Antibody Antibody . TLX250: Phase II STARLITE 1 & 2 therapeutic studies (in combination with immunotherapy) initiated Targeting agent DFO- girentuximab DOTA- girentuximab Rationale: . CA9 is over-expressed in mutated ccRCC and many hypoxic solid tumors, with low expression in most normal tissue Radionuclide 89 Zr 177 Lu Tumour hypoxia correlates with progression and resistance to therapy • Potential for targeted radiation to enhance the effect of existing ccRCC therapies such as immunotherapy Limited competition in imaging, optimises surgical management Telix Pharmaceuticals Limited (ASX: TLX) 39 TELIX PHARMACEUTICALS
View entire presentation